Specified drug use-results survey of TALVEY Subcutaneous Injection in patients with relapsed or refractory multiple myeloma

Specified drug use-results survey of TALVEY Subcutaneous Injection in patients with relapsed or refractory multiple myeloma - TAL1L

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059272

Enrollment

100

Registered

2025-12-01

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received subcutaneous injection of TELVY for the first time in patients with relapsed or refractory multiple myeloma (only when standard treatments are difficult).

Exclusion criteria

Exclusion criteria: OFF LABEL USE

Design outcomes

Primary

Measure	Time frame
To collect adverse event information and evaluate the safety in patients who receive this drug for the first time. Observation period: 12 months from the date of treatment commencement (52 weeks) (allowance: 14 days) *However, if observation becomes impossible by the end of the observation period due to transfer of a registered patient, death, etc., the observation period will end at the time point when observation becomes impossible.	—

Measure

Time frame

To collect adverse event information and evaluate the safety in patients who receive this drug for the first time. Observation period: 12 months from the date of treatment commencement (52 weeks) (allowance: 14 days) *However, if observation becomes impossible by the end of the observation period due to transfer of a registered patient, death, etc., the observation period will end at the time point when observation becomes impossible.

—

Countries

Japan

Contacts

Public ContactFumi Nomura

R & D Medical affairs Delivery unit

fnomura@its.jnj.com03-4411-5136

Outcome results